Albendazole in the treatment of opisthorchiasis and concomitant intestinal helminthic infections.

Abstract

A total of 52 adult patients with opisthorchiasis with or without concomitant intestinal helminthic infections were treated with albendazole at dosage regimens of 400 mg twice daily for 3 days (group I with 25 patients) and 7 days (group II 27 patients). By concentration method with four examinations from two faecal specimens of each patient the cure rates and percentage egg reduction on day 30 in group I and group II were 12% and 33%, 94 and 95 respectively; by Stoll method the cure rates and percentage egg reduction were 40% and 63%, 92 and 92 in group I and group II, respectively. There were no statistically significant differences between the results of the two regimens. Twenty six patients with hookworm and 9 patients with S. stercolaris infections were cured. Opisthorchis viverrini, N. americanus, A. duodenale, A. ceylanicum, E. malayanum, E. ilocanum, S. stercolaris, E. vermicularis, and T. saginata segments were expelled in stools, mostly on days 1 to 4. Most of the patients felt relieved from symptoms of pain in the right hypochondrium and epigastrium. The side effects were mild and transient. There were no evidence of toxic effects on the bone marrow, heart, liver or kidneys. Albendazole was shown to be effective against Opisthorchis viverrini infection as well as other concomitant intestinal helminthic infections; but the optimal dosage and duration of treatment have not yet been achieved.

• Authors: S Pungpark, D Bunnag, T Harinasuta
• Journal: The Southeast Asian journal of tropical medicine and public health (Southeast Asian J Trop Med Public Health) Vol. 15 Issue 1 Pg. 44-50 (Mar 1984) ISSN: 0125-1562 [Print] Thailand
• PMID: 6377514 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anthelmintics
• Benzimidazoles
• Albendazole

Topics

• Adolescent
• Adult
• Aged
• Albendazole
• Anthelmintics (therapeutic use)
• Benzimidazoles (therapeutic use)
• Cestode Infections (complications)
• Clinical Trials as Topic
• Female
• Humans
• Intestinal Diseases, Parasitic (drug therapy)
• Male
• Middle Aged
• Nematode Infections (complications)
• Opisthorchiasis (complications, drug therapy)